Abstract:Precision cancer medicine is widely established, and numerous molecularly targeted drugs for various tumor entities are approved or in development. Personalized pharmacotherapy in oncology has so far been based primarily on tumor characteristics, e.g., somatic mutations. However, the response to drug treatment also depends on pharmacological processes summarized under the term ADME (absorption, distribution, metabolism, and excretion). Variations in ADME genes have been the subject of intensive research for more than five decades, considering individual patients' genetic makeup, referred to as pharmacogenomics (PGx). The combined impact of a patient's tumor and germline genome is only partially understood and often not adequately considered in cancer therapy. This may be attributed, in part, to the lack of methods for combined analysis of both data layers. Optimized personalized cancer therapies should, therefore, aim to integrate molecular information about the tumor and the germline, taking into account existing PGx guidelines for drug therapy. Moreover, such strategies should provide the opportunity to consider genetic variants of previously unknown functional significance. Bioinformatic analysis methods and corresponding algorithms for data interpretation need to be developed to consider PGx data in interdisciplinary molecular tumor boards, where cancer patients are discussed to provide evidence-based recommendations for clinical management based on individual tumor profiles. Significance Statement The era of personalized oncology has seen the emergence of drugs tailored to genetic variants associated with cancer biology. However, full potential of targeted therapy remains untapped due to the predominant focus on acquired tumor-specific alterations. Optimized cancer care must integrate tumor and patient genomes, guided by pharmacogenomic principles. An essential prerequisite for realizing truly personalized drug treatment of cancer patients is the development of bioinformatic tools for comprehensive analysis of all data layers generated in modern precision oncology programs.

Clinical cancer genomics and personalized treatment

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer

Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Comes of Age:Individualized Medicine in Cancer Therapy

Personalized And Dynamic Therapy For Gastric Cancer: A Perspective

Multi-parameter Systematic Strategy Opinion That Predicts, Prevents, and Personalized Treats a Cancer

Personalized medicine: Clinical oncology on molecular view of treatment

Individualized Cancer Therapy, Future Approaches

Personalized Medicine: Recent Progress in Cancer Therapy

Advances in Personalized Oncology

Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes

Proteomics, Personalized Medicine and Cancer

[Multi-Gene Assay Profiling Testing and Individualized Therapy in Breast Cancer].

Personalized drugs: a new opportunity for translational research

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer

Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination – An effective strategy to improve clinical treatment

Toward personalized treatment approaches for non-small-cell lung cancer